In particular, ERβ activation by selective agonists was found to inhibit the growth of non-Hodgkin lymphoma (NHL, the significantly more frequent form of lymphoma, constituting about 90% of cases), mainly by reducing cell proliferation [106,107]. Here, ESR2 is linked to lymphoma.